Armata Pharmaceuticals (ARMP) Return on Capital Employed (2014 - 2026)
Armata Pharmaceuticals (ARMP) posted Return on Capital Employed of 58.07% for Q1 2026, down 17.69% sequentially from 49.34% in Q4 2025, and down 22856.0% YoY from N/an in Q1 2025.
Armata Pharmaceuticals (ARMP) Return on Capital Employed (2014 - 2026) Analysis & Trends
Armata Pharmaceuticals has reported Return on Capital Employed for 13 years, with the latest figure at 58.07% in Q1 2026.
- Quarterly Return on Capital Employed fell 22856.0% year-over-year to 58.07% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 58.07% (down 22856.0% YoY) and the FY2025 annual result came in at 50.38%, up 4573.0% from the prior year.
- Return on Capital Employed fell to 58.07% in Q1 2026 per ARMP's latest filing, from 49.34% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 5801.9% in Q1 2024 and troughed at 96.26% in Q4 2024.
- A 5-year average of 369.42% and a median of 36.32% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed soared 587955 bps in 2024, then slumped 563141 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 53.17% in 2022, then advanced by 14 bps to 45.89% in 2023, then plunged by 110 bps to 96.26% in 2024, then jumped by 49 bps to 49.34% in 2025, then fell by 18 bps to 58.07% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 58.07%, 49.34%, and 60.86% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Armata Pharmaceuticals | 162.98 Mn | 138.98 Mn | - | 23.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.89% |
| Mar 31, 2026 | -58.07% |
| Dec 31, 2025 | -49.34% |
| Sep 30, 2025 | 60.86% |
| Jun 30, 2025 | 97.96% |
| Mar 31, 2025 | 170.49% |
| Dec 31, 2024 | -96.26% |
| Sep 30, 2024 | 277.83% |
| Jun 30, 2024 | 475.41% |
| Mar 31, 2024 | 5,801.90% |
| Dec 31, 2023 | -45.89% |
| Sep 30, 2023 | -48.93% |
| Jun 30, 2023 | -74.72% |
| Mar 31, 2023 | -77.65% |
| Dec 31, 2022 | -53.17% |
| Sep 30, 2022 | -36.32% |
| Jun 30, 2022 | -31.12% |
| Mar 31, 2022 | -32.91% |
| Dec 31, 2021 | -46.34% |
| Sep 30, 2021 | -60.23% |